Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 696,800 shares, a growth of 8.9% from the August 15th total of 640,100 shares. Currently, 6.0% of the company’s stock are sold short. Based on an average daily volume of 150,500 shares, the short-interest ratio is presently 4.6 days.

Institutional Trading of Aadi Bioscience

Hedge funds have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new stake in shares of Aadi Bioscience in the first quarter valued at approximately $294,000. TD Asset Management Inc. acquired a new stake in shares of Aadi Bioscience in the fourth quarter valued at approximately $840,000. Northern Trust Corp acquired a new stake in shares of Aadi Bioscience in the fourth quarter valued at approximately $889,000. 683 Capital Management LLC acquired a new stake in shares of Aadi Bioscience in the fourth quarter valued at approximately $435,000. Finally, Neville Rodie & Shaw Inc. acquired a new stake in Aadi Bioscience during the 2nd quarter worth approximately $164,000. 63.00% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Stock Performance

Shares of NASDAQ AADI opened at $12.50 on Monday. The stock has a 50 day moving average price of $13.13 and a 200 day moving average price of $14.66. Aadi Bioscience has a 52 week low of $11.00 and a 52 week high of $32.99. The stock has a market capitalization of $262.71 million, a PE ratio of -1.09 and a beta of 1.49.

About Aadi Bioscience

(Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

See Also

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.